Chondroitin sulfate functionalized mesostructured silica nanoparticles as biocompatible carriers for drug delivery

Abstract

Mesoporous silica nanoparticles (MSNs) have garnered a great deal of attention as potential carriers for therapeutic payloads. Here, we report a pH-responsive drug-carrier based on chondroitin sulfate functionalized mesostructured silica nanoparticles (NMChS-MSNs) ie, the amidation between NMChS macromer and amino group functionalized MSNs. The prepared nanoparticles were characterized using dynamic light scattering, fourier transform infrared spectroscopy and transmission electron microscopy. The resultant NMChS-MSNs were uniform spherical nanoparticles with a mean diameter of approximately 74 nm. Due to the covalent graft of hydrophilic and pH responsive NMChS, the NMChS-MSNs could be well dispersed in aqueous solution, which is favorable to being utilized as drug carriers to construct a pH-responsive controlled drug delivery system. Doxorubicin hydrochloride (DOX), a well-known anticancer drug, could be effectively loaded into the channels of NMChS-MSNs through electrostatic interactions between drug and matrix. The drug release rate of DOX@NMChS-MSNs was pH dependent and increased with the decrease of pH. The in vitro cytotoxicity test indicated that NMChS-MSNs were highly biocompatible and suitable to use as drug carriers. Our results imply that chondroitin sulfate functionalized nanoparticles are promising platforms to construct the pH-responsive controlled drug delivery systems for cancer therapy.

Endostatin Genetically Engineered Placental Mesenchymal Stromal Cells Carrying Doxorubicin-Loaded Mesoporous Silica Nanoparticles for Combined Chemo- and Antiangiogenic Therapy

“…These particles presented an initial burst release (26.82 ± 1.74% drug released at 3 h) followed by a sustained DOX release at 37 • C in PBS, with 50.81 ± 5.11% of drug released within 7 d ( Figure S1). These values are in good agreement with those for similar DOX release MSNs reported in the literature [40][41][42].…”

Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules

“…Similarly, chitosan [188][189][190] and chondroitin sulfate [191][192][193] were employed for the development of high colloidally stable and biocompatible nanosystems with certain targeting capabilities. Moreover, as both substances are important structural components of extracellular matrices on vertebrates and crustaceans, they can act as bioactive components for tissue regeneration.…”

Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery

“…Therefore, the melanocytes would also be exposed to both anti-MCS-PG monoclonal antibodies and immune-toxin mediated attack strategies [ 118 , 119 ]. Xi et al [ 120 , 121 ] prepared a CS nanocapsule loaded with indomethacin for delivery and demonstrated its pH responsiveness when studied in vitro in a pharmacological drug release model. Xi et al [ 121 ] also prepared functionalized mesoporous silica nanoparticles (MSNs) with CS coronas (NMCS-MSN), which exhibited high drug loading capacity and pH-triggered controlled release of drug simultaneously.…”

“…Xi et al [ 120 , 121 ] prepared a CS nanocapsule loaded with indomethacin for delivery and demonstrated its pH responsiveness when studied in vitro in a pharmacological drug release model. Xi et al [ 121 ] also prepared functionalized mesoporous silica nanoparticles (MSNs) with CS coronas (NMCS-MSN), which exhibited high drug loading capacity and pH-triggered controlled release of drug simultaneously. Typically, NMCS-MSN was mixed with test drug doxorubicin to form NMCS-MSN-Dox that was then cross-linked with bisulfate.…”